Tirofiban Hydrochloride is Used for reducing thrombotic coronary events in patients with acute coronary syndrome. It was first introduced by Medicure International Inc in its drug Aggrastat on May 14, 1998. 4 different companies have introduced drugs containing Tirofiban Hydrochloride.

Tirofiban Hydrochloride Patents

Given below is the list of patents protecting Tirofiban Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Aggrastat	US6770660	Method for inhibiting platelet aggregation	May 01, 2023 (Expired)	Medicure
Aggrastat	US6136794	Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist	Jan 29, 2019 (Expired)	Medicure
Aggrastat	US5978698	Angioplasty procedure using nonionic contrast media	Oct 08, 2017 (Expired)	Medicure
Aggrastat	US5733919	Compositions for inhibiting platelet aggregation	Oct 23, 2016 (Expired)	Medicure
Aggrastat	US5733919	Compositions for inhibiting platelet aggregation	Oct 23, 2016 (Expired)	Medicure
Aggrastat	US5965581	Compositions for inhibiting platelet aggregation	Oct 23, 2016 (Expired)	Medicure
Aggrastat	US5972967	Compositions for inhibiting platelet aggregation	Oct 23, 2016 (Expired)	Medicure

Add above patents to watchlist

Tirofiban Hydrochloride's Family Patents

Full family tree

Tirofiban Hydrochloride Generic API Manufacturers

Several generic applications have been filed for Tirofiban Hydrochloride. The first generic version for Tirofiban Hydrochloride was by Gland Pharma Ltd and was approved on Apr 8, 2021. And the latest generic version is by Nexus Pharmaceuticals Llc and was approved on Jul 24, 2023.

Given below is the list of companies who have filed for Tirofiban Hydrochloride generic, along with the locations of their manufacturing plants worldwide.